Karin Bergstein

🎉 Exciting news! In case you haven’t heard, we launched our new digital magazine in March: Insights by Servier!   In the first edition, we had the pleasure of chatting about research in rare diseases with Nicolas Levy, physician and researcher in medical genetics, and Chief Scientist Rare Diseases at Servier. ➡️ How can we define rare diseases? ➡️ How are things progressing in terms of new rare disease identification? ➡️ Advances in diagnosis and therapeutic approaches ➡️ Is it possible to cure a rare disease? ➡️ What are the major challenges in this area?   You’ll find all the answers in our interview at 👉 https://lnkd.in/eBTC-jga   #WeAreServier #InsightsByServier #RareDiseases

123

2 Kommentare

Gain insights into drug delivery via an on-body patch infusor developed by Gerresheimer from Sabine Websky, Head of Medical Affairs & Applied Technologies! The subcutaneous route of drug administration is increasingly popular, particularly self-administration, due to the high costs associated with intravenous administration and the patient advantages of therapy in a home-care setting. This presentation looks at the advantages of subcutaneous delivery compared to intravenous administration. It further discusses the effectiveness of subcutaneous delivery of small molecule drugs via an on-body infusor. Evidence will be presented from clinical studies of a novel furosemide formulation delivered subcutaneously via an on-body patch infusor developed by Gerresheimer. Gerresheimer is a Silver Sponsor at Combination Products Summit! Be sure to stop by their booth and say hello 👋 ! Register for this conference or learn more on our website: https://lnkd.in/eY8w4jNc #combinationproducts #clinicalstudy #infusor #drugadministration #medicaldevices #biotechnology #drugdelivery #pharmaevent

4

We are happy to support you in the authorization process for pharmaceuticals and medical devices in Switzerland with specialized translations that comply with all regulatory requirements and Swissmedic guidelines thanks to our 26 years of experience. 💊 #SWISSMEDIC #translation

15

🤝 𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 𝗔𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝗺𝗲𝗻𝘁: 𝗘𝗰𝗸𝗲𝗿𝘁 & 𝗭𝗶𝗲𝗴𝗹𝗲𝗿 supports 𝗧𝗲𝗹𝗶𝘅 in Groundbreaking 𝗣𝗵𝗮𝘀𝗲 𝗜𝗜𝗜 𝗦𝘁𝘂𝗱𝘆! 📢 Eckert & Ziegler has become the 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗰𝗼𝗻𝘁𝗿𝗮𝗰𝘁 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗲𝗿 for Telix Pharmaceuticals Limited's innovative 𝗣𝗵𝗮𝘀𝗲 𝗜𝗜𝗜 𝗣𝗿𝗼𝘀𝘁𝗔𝗖𝗧 𝗚𝗟𝗢𝗕𝗔𝗟 𝘀𝘁𝘂𝗱𝘆. Our state-of-the-art 𝗚𝗠𝗣 𝘀𝘂𝗶𝘁𝗲 𝗶𝗻 𝗕𝗲𝗿𝗹𝗶𝗻 will play a pivotal role in supplying the 𝗲𝗻𝘁𝗶𝗿𝗲 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗯𝗮𝘀𝗲, as well as providing the crucial 𝘀𝘁𝗮𝗿𝘁𝗶𝗻𝗴 𝗺𝗮𝘁𝗲𝗿𝗶𝗮𝗹—our high-purity, non-carrier added 𝗚𝗠𝗣-𝗴𝗿𝗮𝗱𝗲 𝗟𝘂𝘁𝗲𝘁𝗶𝘂𝗺-𝟭𝟳𝟳. 📊  𝗣𝗵𝗮𝘀𝗲 𝗜𝗜𝗜 𝗣𝗿𝗼𝘀𝘁𝗔𝗖𝗧 𝗚𝗟𝗢𝗕𝗔𝗟 𝗦𝘁𝘂𝗱𝘆 Highlights: • The study is exploring the benefits and risks of 𝗟𝘂𝘁𝗲𝘁𝗶𝘂𝗺 (𝗟𝘂 𝟭𝟳𝟳) 𝗿𝗼𝘀𝗼𝗽𝗮𝘁𝗮𝗺𝗮𝗯 𝘁𝗲𝘁𝗿𝗮𝘅𝗲𝘁𝗮𝗻 in adult males with prostate-specific membrane antigen (𝗣𝗦𝗠𝗔) 𝗽𝗼𝘀𝗶𝘁𝗶𝘃𝗲 𝗽𝗿𝗼𝘀𝘁𝗮𝘁𝗲 𝗰𝗮𝗻𝗰𝗲𝗿. • The treatment will be in 𝗰𝗼𝗺𝗯𝗶𝗻𝗮𝘁𝗶𝗼𝗻 with the 𝘀𝘁𝗮𝗻𝗱𝗮𝗿𝗱 𝗼𝗳 𝗰𝗮𝗿𝗲 💬 “We are happy to further expand our long-standing and s𝘂𝗰𝗰𝗲𝘀𝘀𝗳𝘂𝗹 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗧𝗲𝗹𝗶𝘅,” said Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE. “This contract underlines not only the importance of our 𝗹𝗲𝗮𝗱𝗶𝗻𝗴-𝗲𝗱𝗴𝗲 𝗳𝗮𝗰𝗶𝗹𝗶𝘁𝘆 𝗶𝗻 𝗕𝗲𝗿𝗹𝗶𝗻, but also our role as an 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝗹 𝘀𝗲𝗿𝘃𝗶𝗰𝗲 𝗽𝗿𝗼𝘃𝗶𝗱𝗲𝗿 in the continuously growing radiopharmaceutical market.” Darren Patti, Group Chief Operating Officer of Telix, added: “The decision to work with 𝗘𝗰𝗸𝗲𝗿𝘁 & 𝗭𝗶𝗲𝗴𝗹𝗲𝗿 is based on their 𝗼𝘂𝘁𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴 𝗲𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲 and the 𝗾𝘂𝗮𝗹𝗶𝘁𝘆 𝗼𝗳 𝘁𝗵𝗲𝗶𝗿 𝗳𝗮𝗰𝗶𝗹𝗶𝘁𝗶𝗲𝘀. We are convinced that this continued strategic partnership will contribute significantly to the success of our ProstACT GLOBAL study.” The collaboration marks an 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁 𝘀𝘁𝗲𝗽 in both companies' ongoing efforts to advance 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 in the field of radiopharmaceuticals. This project is just one example of the 𝗰𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀 of Eckert & Ziegler's 𝗴𝗹𝗼𝗯𝗮𝗹 𝗚𝗠𝗣 𝘀𝘂𝗶𝘁𝗲𝘀. 🚀 🔗 For more details and the 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲, follow the 𝗹𝗶𝗻𝗸 down in the 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝘀 🔽 #ContributingToSavingLives #NuclearMedicine #Radiopharmaceuticals #PrecisionMedicine #RadioligandTherapy

247

5 Kommentare